Health and Fitness Health and Fitness
Wed, February 16, 2011
Tue, February 15, 2011
Mon, February 14, 2011
Fri, February 11, 2011
Thu, February 10, 2011
Wed, February 9, 2011
Tue, February 8, 2011
Mon, February 7, 2011
[ Mon, Feb 07th 2011 ] - Market Wire
00 A.M. EST
Sun, February 6, 2011
Fri, February 4, 2011
Thu, February 3, 2011
Wed, February 2, 2011
Tue, February 1, 2011
Mon, January 31, 2011
Sun, January 30, 2011
Fri, January 28, 2011
Thu, January 27, 2011
[ Thu, Jan 27th 2011 ] - Market Wire
Tatler Pacific Acquires Euoko

Marina Biotech, Inc. to Present at The 13th Annual BIO CEO & Investor Conference


//health-fitness.news-articles.net/content/2011/ .. the-13th-annual-bio-ceo-investor-conference.html
Published in Health and Fitness on Tuesday, February 8th 2011 at 6:40 GMT by Market Wire   Print publication without navigation


BOTHELL, WA--(Marketwire - February 8, 2011) - Marina Biotech, Inc. (NASDAQ: [ MRNA ]), a leading RNAi-based drug discovery and development company, announced today that it will present at The 13th Annual BIO CEO & Investor Conference on Monday, February 14, 2011, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) at the Waldorf-Astoria in New York City. J. Michael French, Marina Biotech President and Chief Executive Officer, will present a corporate overview and business update.

A live audio webcast will be available on the Event Calendar pages of the Investors section of the Company's website at [ http://www.marinabio.com ]. Please allow time prior to the presentation to register and download any necessary software. A replay of the presentation will be available on the Investors section of the Marina Biotech website under Event Calendar approximately one hour after the live presentation.

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company, focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech has recently entered an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at [ http://www.marinabio.com ].


Publication Contributing Sources